Baolingbao Biology Co.,Ltd.

BAOLINGBAO BIOLOGY CO.,LTD is a leading Chinese producer of starch-based health and food ingredients. The company mainly provide erythritol, isomaltitol L-glutamine, isomaltooligosaccharide-900/500, malto-oligosacchardie, xylo-oligosaccharide, fructo-oligosaccharide, indigestible dextrin, polydextrose, beta-cyclodextrin, high fructose corn syrup, dextrose monohydrate, liquid glucose,Corn gluten meal and so on.

Related News

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

news image

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More

CELL AND GENE THERAPY

PERKINELMER COMPLETES ACQUISITION OF ANTIBODY AND REAGENT LEADER BIOLEGEND

PerkinElmer | September 18, 2021

news image

PerkinElmer, Inc.a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant protei...

Read More

MEDICAL

ANIXA BIOSCIENCES ANNOUNCES THE INITIATION OF ITS OVARIAN CANCER CAR-T PHASE 1 TRIAL AT MOFFITT CANCER CENTER

Anixa | March 31, 2022

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will ev...

Read More

CELL AND GENE THERAPY

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

news image

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More
news image

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More
news image

CELL AND GENE THERAPY

PERKINELMER COMPLETES ACQUISITION OF ANTIBODY AND REAGENT LEADER BIOLEGEND

PerkinElmer | September 18, 2021

PerkinElmer, Inc.a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant protei...

Read More
news image

MEDICAL

ANIXA BIOSCIENCES ANNOUNCES THE INITIATION OF ITS OVARIAN CANCER CAR-T PHASE 1 TRIAL AT MOFFITT CANCER CENTER

Anixa | March 31, 2022

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will ev...

Read More
news image

CELL AND GENE THERAPY

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More